Introduction {#Sec1}
============

In 2005, Goetz et al. reported the first study in which a positive association was found between the cytochrome P450 2D6 isoenzyme (CYP2D6) genotype and tamoxifen efficacy in early breast cancer patients \[[@CR1]\]. Previously, it was demonstrated that genetic variants of CYP2D6, leading to an enzyme with impaired or absent activity, resulted in lower blood concentrations of the most important active tamoxifen metabolite, endoxifen \[[@CR2], [@CR3]\]. At present, the discussion whether CYP2D6 activity is a relevant predictor of tamoxifen response is still timely, although conflicting data have created much controversy \[[@CR1], [@CR4]--[@CR12]\]. The variance of endoxifen blood concentrations among the separate CYP2D6 phenotypes (poor (PM), intermediate (IM), extensive (EM), and ultrarapid metabolizers (UM)) is large and may have contributed to these conflicting data. The CYP2D6 genotype only partially predicts endoxifen blood levels (*r*^2^ = 23--43 %); therefore, endoxifen concentration itself may be a better predictor of tamoxifen response \[[@CR3], [@CR13]\]. Many studies have investigated the in vitro effects of endoxifen leading to the general belief that endoxifen is the most important active tamoxifen metabolite \[[@CR2], [@CR3], [@CR14]--[@CR16]\]. However, no prospective study to date has directly addressed the possible association between endoxifen blood levels in patients and efficacy. In the Women's Healthy Eating and Living (WHEL) study, the first retrospective correlation between endoxifen concentration and breast cancer survival was made \[[@CR17]\]. Patients with endoxifen levels in the range of the lowest quintile had a 35 % higher rate of breast cancer events suggesting a threshold effect with a reported endoxifen threshold of 5.97 ng/ml (=16.0 nM). In this study, 76 % of the CYP2D6 poor metabolizers had endoxifen levels within the range of the lowest quintile. This study, however, was not designed for this purpose and the borderline significant difference in outcome between the patients with the lowest endoxifen levels (lowest quintile) and the patients with higher endoxifen levels (HR = 0.74; 95 % CI 0.55--1.00) should be interpreted with caution. Patients with low endoxifen blood concentrations may experience less tamoxifen efficacy and may require a tamoxifen dose higher than the standard 20 mg once daily dose. In contrast, increasing the tamoxifen dosage to 90 mg daily did not affect tamoxifen response in metastatic breast cancer patients compared to a standard dose of 30 mg daily with equal response rate and duration. The investigators of this small study however did not account for CYP2D6 genotype or endoxifen level \[[@CR18]\]. CYP2D6 intermediate and poor metabolizers with low endoxifen levels may still benefit from higher tamoxifen doses.

In a recent study, the feasibility of increasing endoxifen concentration in intermediate (IMs) and poor metabolizers (PMs) was demonstrated \[[@CR19]\]. By increasing the 20 mg tamoxifen dose in IMs and PMs to 40 mg once daily, endoxifen levels were significantly increased. The increased endoxifen levels in IMs using 40 mg tamoxifen did not significantly differ with the endoxifen concentration found in extensive metabolizers (EMs) using the standard dosage, while the increased endoxifen levels in the dose escalated PMs were still significantly lower. Therefore, PMs and some IMs may need more than a double tamoxifen dose in order to reach the mean endoxifen level found in EMs. How to calculate the necessary tamoxifen dose and whether higher doses of tamoxifen can be safely used to reach this goal is unknown. In metastatic breast cancer and other advanced tumor types, a tamoxifen dose up to 120 mg daily seems tolerable with limited side effects during a short period of time \[[@CR18], [@CR20]--[@CR24]\].

In The Netherlands and Belgium, a prospective study (CYPTAM study: NTR1509) has included 650 early breast cancer patients using tamoxifen to relate predicted CYP2D6 phenotype and endoxifen serum concentration to disease-free survival \[[@CR25]\]. Patients with a CYP2D6 poor or intermediate metabolizer phenotype who were still treated with tamoxifen could be included in a pharmacokinetic study. The aim of the current pharmacokinetic study is to investigate the effect of a temporary one-step tamoxifen dose escalation on endoxifen serum concentration and toxicity in poor and intermediate metabolizers.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

From February 2008 until December 2010, 650 early breast cancer patients who were using tamoxifen as a part of an adjuvant treatment were included in a multicenter study in The Netherlands and Belgium aiming to relate CYP2D6-predicted phenotype and endoxifen serum concentrations to breast cancer survival (CYPTAM study) \[[@CR25]\]. These patients were genotyped for genetic variants in the CYP2D6 gene and were classified into an ultrarapid (UM), extensive (EM), intermediate (IM), or poor metabolizer (PM) CYP2D6 phenotype. Pre- and postmenopausal women (≥18 years) with hormone receptor positive early breast cancer treated with adjuvant tamoxifen after tumor resection were eligible for the subsequent pharmacokinetic study if they had no medical history of another malignancy or a venous thromboembolic event, were not pregnant or breastfeeding, had a normal QT-interval on ECG registration, hemoglobin ≥6.0 mmol/L, WBC ≥3.0 × 109/L, platelets ≥100 × 109/L, bilirubin within normal limits, ASAT and ALAT ≤2.5 times the upper limit of normal, and if they had a poor or intermediate metabolizer phenotype (12 PMs and 12 IMs). Patients should be using tamoxifen for more than 2 months. Concomitant use of a CYP2D6 inhibitor was permitted.

CYP2D6 predicted phenotype {#Sec4}
--------------------------

CYP2D6 genotyping was performed using the Amplichip CYP450 test (Roche Diagnostics, Indianapolis, US) to test the major CYP2D6 alleles (33) on whole blood. CYP2D6 genotypes were translated to predicted phenotypes (ultrarapid (UM), extensive (EM), intermediate (IM), or poor metabolizer (PM)). By definition, the CYP2D6 IM phenotype predicted by genotype consisted of patients homozygous for a decreased activity allele (e.g., \*41/\*41) or heterozygous for an absent activity allele (e.g., \*1/\*4 and \*41/\*4). In contrast, the Amplichip test translates the genotype with one absent and one normal activity allele (e.g., \*1/\*4) into an EM phenotype. This genotype is sometimes translated into a heterozygous extensive metabolizer phenotype (hetEM). Previously, we have shown that hetEM is a distinct phenotype with a mean endoxifen level in between the extensive and true intermediate metabolizer phenotype \[[@CR13]\]. Additionally, concomitant use of a CYP2D6 inhibitor could reclassify the CYP2D6 phenotype predicted by genotype \[[@CR26]\].

Study design {#Sec5}
------------

After enrollment in the CYPTAM study, whole blood and serum samples were retrieved for CYP2D6 genotyping and measurement of tamoxifen and its metabolites after ≥2 months of tamoxifen use, ensuring steady state endoxifen levels. The time interval between serum sample retrieval and the last tamoxifen intake had to be more than 12 h to obtain endoxifen trough levels. Patients with a CYP2D6 PM and IM phenotype were informed and asked to participate in a genotype-directed dose escalation study until 12 patients were included from each phenotype group and initiated the tamoxifen dose escalation. Inclusion only took place after written-informed consent was obtained at the Leiden University Medical Center. All patients were initially treated with the standard dose of 20 mg tamoxifen once daily. The 12 PMs and 12 IMs included in the pharmacokinetics study participated in a temporary one-step tamoxifen dose escalation during 2 months. The individual patient's baseline endoxifen serum concentration was determined by calculating the mean of two separate endoxifen measurements in time. Previously, the average endoxifen serum concentration in EMs of 33.7 nM (7.2--87.3) was determined by using the median endoxifen level in the first 586 patients included in the CYPTAM documentation study just before initiating the pharmacokinetics study at that time consisting of 292 EMs \[[@CR13]\]. Based on the pharmacokinetics of other metabolites, during different low doses of tamoxifen up to 20 mg, we hypothesized that endoxifen levels would also be linearly increased by further escalating the tamoxifen dose \[[@CR27]\]. As a linear increase in endoxifen plasma concentration was assumed with increasing tamoxifen doses, the individual tamoxifen escalation dose was calculated by the formula: 20 mg × (average endoxifen serum concentration in EMs/patient's baseline endoxifen serum concentration). The tamoxifen escalation dose was limited to a maximal dose of 120 mg once daily for reasons of safety. Calculated escalation dosage was rounded off upwards or downwards to every 10 mg. Patients were instructed to use the tamoxifen escalation dose for the duration of 2 months until the next determination of endoxifen serum concentration or earlier if severe toxicity occurred. After 2 months of using the increased tamoxifen dose, a next serum sample was retrieved, and the patient returned to the standard daily dose of 20 mg. Toxicity was assessed at 1, 2, and 3 months after the starting date of the tamoxifen dose escalation using the National Cancer Institute Common Toxicity Criteria for Adverse Events, version 3.0. ECGs were made, and blood samples were drawn for serum biochemistry and hematology at baseline, and at 2 months of dose escalation. The current study was approved by the central medical ethics review board of the Leiden University Medical Center in Leiden, The Netherlands. All patients gave written-informed consent before entering the study.

Tamoxifen and metabolite measurement {#Sec6}
------------------------------------

Serum concentrations of tamoxifen and its metabolites were measured by using a high-performance liquid chromatography-tandem mass spectrometry (HPLC LC/MS/MS) assay for the detection of tamoxifen and three metabolites in human serum. The HPLC LC/MS/MS assay was developed and validated for the purpose of the CYPTAM study at the laboratory of Clinical Pharmacy and Toxicology at the Leiden University Medical Center and is similar to a previously described method \[[@CR28]\]. Tamoxifen, *N*-desmethyltamoxifen (NDMTam), and the main active metabolites 4-hydroxytamoxifen (4OHTam) and 4-hydroxy-*N*-desmethyltamoxifen (endoxifen) were accurately detected and quantified (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Tamoxifen metabolism. *4OHTam* 4-hydroxytamoxifen, *CYP* cytochrome P450 isoenzyme, *SULT* sulfotransferase, *UGT* UDP-glucuronosyltransferase, *NDMTam* *N*-desmethyltamoxifen, *NR1* nuclear receptor subfamily 1, *PXR* pregnane X receptor, *CAR* constitutive androstane receptor

Statistical methods {#Sec7}
-------------------

Tamoxifen, NDMTam, 4OHTam, and endoxifen serum concentrations were measured three times in PMs and IMs: (1) at entering the CYPTAM study, (2) before tamoxifen dose escalation and (3) at 2 months of dose escalation. A paired *T* test was used to test the null hypothesis that the change in concentration of endoxifen and other tamoxifen metabolites at 2 months of dose escalation from baseline equals zero. A one sample *T* test was used to test the difference between endoxifen serum concentration at 2 months of tamoxifen dose escalation in PMs and IMs and the median endoxifen level in EMs without dose escalation (33.7 nM). Side effects were dichotomized (hot flushes: grade 0--1 vs. 2--3, other side effects: grade 0 vs. grade ≥1), and the difference between side effects before and at 2 months of dose escalation were tested using the McNemar's Chi-squared test.

Results {#Sec8}
=======

In the current pharmacokinetics study, 12 PMs and 12 IMs were included and started dose escalation. The baseline characteristics of these 24 patients are shown in Table [1](#Tab1){ref-type="table"}. Most patients were postmenopausal, three IMs and one PM were premenopausal. Mean age was 53.9 years for PMs and 52.4 years for IMs. The mean BMI was notably higher in PMs than in IMs (29.4 and 26.7 kg/m^2^). One patient used venlafaxine, a weak CYP2D6 inhibitor. Another patient used paroxetine, a strong CYP2D6 inhibitor during tamoxifen use. All patients were using tamoxifen for more than 2 months ensuring steady state concentrations of tamoxifen and its metabolites (mean 22.5 months, range 12.0--56.6 months). Of the 12 PMs who started dose escalation, one stopped after \~2 weeks because of toxicity at a tamoxifen dose of 60 mg. One PM completed the 2 months of 90 mg dose escalation; unfortunately, the last serum sample was not properly obtained. Thus, for the comparison of endoxifen and other metabolite concentration before and at 2 months of dose escalation, 22 patients were analyzed. Toxicity was evaluated in 24 patients.Table 1Baseline characteristics of 24 early breast cancer patientsCYP2D6 phenotypeIM (*n* = 12)PM (*n* = 12)Mean age in years (range; SD)52.4 (41.5--71.0; 8.7)53.9 (40.7--67.7; 8.0)Mean BMI in kg/m^2^ (range; SD)26.7 (20.6--34.5; 4.2)29.4 (21.0--42.8; 6.7)Menopausal status Premenopausal31 Postmenopausal811 Unknown10Mean tamoxifen duration in months (range)23.3 (14.0--56.6)21.8 (12.0--34.7)CYP2D6 genotypes\*1/\*4 (*n* = 2)\*3/\*4 (*n* = 2)\*2/\*4 (*n* = 6)\*4/\*4 (*n* = 7)\*2/\*5 (*n* = 2)\*4/\*5 (*n* = 2)\*4/\*41 (*n* = 2)\*5/\*6CYP2D6 inhibitor use1 (venlafaxine)1 (paroxetine)*IM* intermediate metabolizer, *PM* poor metabolizer, *n* number of patients, *SD* standard deviation

The mean tamoxifen escalation dose for the 12 IMs was 46 mg (range 30--100 mg) and 90 mg (range 60--120 mg) for 10 PMs, who all completed the 2 months dose escalation (Table [2](#Tab2){ref-type="table"}). The endoxifen serum concentrations in both PMs and IMs were significantly increased compared to the concentrations measured at baseline (PMs: from 8.0 nM to 27.3 nM, *p* \< 0.001; IMs: from 17.8 nM to 30.3 nM, *p* = 0.002) as shown in Table [2](#Tab2){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}. Compared to the median endoxifen concentration in EMs using a normal 20 mg tamoxifen dose (=33.7 nM), there was no significant difference with the mean endoxifen level after dose escalation in IMs (=30.3 nM; *p* = 0.20), although the mean endoxifen level in PMs after dose escalation was significantly lower (=27.3 nM; *p* = 0.03) as shown in Table [2](#Tab2){ref-type="table"}. Serum tamoxifen and the other metabolites were also significantly increased following dose escalation (Supplementary Table 4).Table 2Serum endoxifen concentrations in IMs and PMs after tamoxifen dose escalation compared to the median serum endoxifen concentration in EMs (33.7 nM)CYP2D6 phenotype*n*\[Endoxifen\] before dose escalation (range; SD)Mean escalated tamoxifen dose (range)\[Endoxifen\] after dose escalation (range; SD)\[Endoxifen\] after dose escalation vs. 33.7 nM in EMsIM1217.8 nM (7.0--27.0; 6.5)46 mg (30--100)30.3 nM^a^ (20.2--50.6; 8.8)*p* = 0.20PM108.0 nM (4.9--11.1; 2.2)90 mg (60--120)27.3 nM^b^ (18.2--44.1; 7.7)*p* = 0.03*IM* intermediate metabolizer, *PM* poor metabolizer, *n* number of patients, *SD* standard deviation^a^Significant increase compared to baseline \[endoxifen\]; *p* \< 0.001^b^Significant increase compared to baseline \[endoxifen\]; *p* = 0.002Fig. 2Endoxifen concentration before and after tamoxifen dose escalation during 2 months in **a** intermediate metabolizers and **b** poor metabolizers. Each *line* represents one patient, starting with a baseline \[endoxifen\] on the *left*, which increases to an \[endoxifen\] after 2 months of dose escalation on the *right*. Median \[endoxifen\] in extensive metabolizers used for calculating the tamoxifen escalation dose. **a** Intermediate metabolizers, **b** poor metabolizers

Toxicity resulted in premature cessation of the escalated dose in one patient using tamoxifen at a dose of 60 mg, although side effects were ≤ grade 2 (grade 1 hot flashes and diarrhea, grade 2 headache, dizziness, and fatigue). One patient using 50 mg of tamoxifen experienced a bothersome grade 2 tendinitis of one of her fingers. On ECG, the QTc in one patient using 100 mg tamoxifen was slightly prolonged at 2 months (464 ms vs. 435 ms at baseline) but normalized 2 weeks after returning to the 20 mg dose (QTc = 436 ms). No grade 3 or 4 toxicity was observed as a result of the dose escalation: only one patient already had grade 3 hot flashes at baseline. Remarkably, in 4 patients, grade 1 hot flashes disappeared during dose escalation. In two of these patients, grade 1 hot flashes reappeared 1 month after returning to the normal dose. Nearly all side effects that increased during tamoxifen escalation returned to baseline values 1 month after cessation of the tamoxifen escalation. No significant differences were found between side effects at baseline and at 2 months of dose escalation (Table [3](#Tab3){ref-type="table"}). Only a nonsignificant increase in grade 1 fatigue (*p* = 0.13) and grade 1 alopecia (*p* = 0.25) was observed.Table 3Comparison between side effects at baseline and 2 months of tamoxifen dose escalation in 12 IMs and 11 PMsAdverse effectBaseline+2 MonthsMcNemar's testGrade 0--1Grade ≥ 2Grade 0--1Grade ≥ 2*p* valueHot flashes IM111930.50 PM110101−^a^ All2211940.25Grade 0Grade ≥1Grade 0Grade ≥1Headache All2032121.00Dizziness All2212121.00Nausea All2212121.00Alopecia IM1111111.00 PM92650.25 All203176^b^0.38Vaginal discharge All2122121.00Vaginal dryness All2122121.00Fatigue IM93660.25 PM92831.00 All185149^b^0.13Ocular All230212--^a^Musculoskeletal All1942031.00*IM* intermediate metabolizer, *PM* poor metabolizer^a^Unable to calculate *p* value^b^All grade 1

Discussion {#Sec9}
==========

In the current CYP2D6 genotype- and endoxifen-guided dose escalation study, we temporarily increased the tamoxifen dose in CYP2D6 intermediate and poor metabolizers in one step to a daily dose of up to 120 mg. This is the first study in which the tamoxifen dose is escalated by using a calculation, based on individual endoxifen concentration at baseline: thus, an individual dose adaptation was made. In previous studies, the tamoxifen dose in poor and intermediate metabolizers was escalated from 20 up to 40 mg, but not in such a personalized manner as described here \[[@CR19], [@CR29], [@CR30]\]. Of note, a better recurrence-free survival but not overall survival was demonstrated in the Oxford overview when using 40 mg instead of 20 mg/day \[[@CR31]\].

Our endoxifen-guided dose escalation resulted in a significant increase of endoxifen serum concentrations in both IMs and PMs. In IMs but not in PMs, dose escalation increased endoxifen to levels comparable with those observed in extensive metabolizers. The endoxifen increase in poor metabolizers is higher than expected from a capacity-limited metabolism with saturation of CYP2D6, especially when CYP2D6 activity is low or even absent. An explanation for the more than threefold increase in endoxifen concentration in PMs may be that other routes leading to endoxifen formation are upregulated. The route leading to endoxifen through the formation of 4OHTam may become more important as, in this route, other enzymes than CYP2D6 are involved (Fig. [1](#Fig1){ref-type="fig"}). Whether this magnitude of endoxifen increase is necessary to make tamoxifen most effective is uncertain; the critical effective endoxifen concentration is unknown, because prospective data are lacking. However, in one retrospective study, an endoxifen threshold of 5.97 ng/ml (=16.0 nM) was suggested \[[@CR17]\]. All 11 PMs and 6 out of 12 IMs started with a baseline endoxifen level below this threshold. Our individualized endoxifen-guided dose escalation managed to increase endoxifen concentrations of all patients to a level above 16 nM (Fig. [2](#Fig2){ref-type="fig"}). Nevertheless, Lash et al. postulated using a model that, even in PMs, tamoxifen and its metabolites are able to bind over 99.6 % of estrogen receptors. Because of the abundance of tamoxifen and its metabolites at the estrogen receptor level regardless of the CYP2D6 genotype, PMs may unlikely have a clinically relevant smaller effect from tamoxifen than EMs \[[@CR7], [@CR32]\].Therefore, we are eagerly awaiting the results from the ongoing prospective studies, addressing the relation between endoxifen and clinical outcome in tamoxifen-treated breast cancer patients (CYPTAM: NTR1509; CYPTAMBRUT-2: NCT00965939; ECOG E3108: NCT01124695).

Tamoxifen dose escalation not only may increase efficacy, but may also increase toxicity. In the current study, an escalated dose up to 120 mg was safe and did not significantly increase side effects. Toxicity, however, caused one patient to stop treatment with an escalated dose of 60 mg. Furthermore, long-term side effects are unknown as all patients returned to the normal 20 mg tamoxifen dose after 2 months. The maximum tamoxifen dosage of 120 mg that was considered safe was based on only a limited amount of studies in metastatic breast cancer and several studies in other advanced tumor types \[[@CR18], [@CR20]--[@CR24]\]. Although the situation of tamoxifen used in other advanced tumor types sometimes combined with cytostatics is difficult to extrapolate to the early breast cancer patient using adjuvant tamoxifen, no severe toxicity was found in literature using up to 120 mg during a short period of time. Tamoxifen retinopathy has been reported when using long-term high doses of tamoxifen (240--320 mg/day) in metastatic breast cancer, while ocular toxicity is uncommon in long-term, low-dose tamoxifen use, leaving uncertainty for doses from 40 up to 120 mg \[[@CR33], [@CR34]\]. However, information on side effects such as endometrial cancer and venous tromboembolism as a result of long-term tamoxifen use at such high dosage is uncertain. As a proxy for the ability of tamoxifen to increase the risk of developing endometrial cancer, we aimed to determine concentrations of α-hydroxytamoxifen, a potential carcinogenic metabolite. Increase of the α-hydroxytamoxifen concentration as result of the tamoxifen dose escalation would potentially also impose an increased endometrial cancer risk. Unfortunately, we were not able to accurately quantify α-hydroxytamoxifen, partly because of analyte instability.

In conclusion, a temporary CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation in CYP2D6 poor and intermediate metabolizers increased endoxifen concentrations without increasing short-term side effects. More than threefold endoxifen increase in PMs suggests upregulation of alternative routes for endoxifen formation. Whether such tamoxifen dose escalation is necessary to increase tamoxifen efficacy in PMs and IMs and whether it is safe in view of long-term toxic effects is unknown and needs to be further explored.
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